Oxfordshire Sedentariness, Obesity & Cardiometabolic Risk in Adolescents - a Trial of Exercise in Schools (OxSOCRATES)

August 4, 2021 updated by: University of Oxford
Obesity is a major cardiovascular disease (CVD) risk factor that is rising fastest in children. Prevention of its damaging effects should begin earlier before they become irreversible. Pilot data identified novel markers of cardiometabolic dysfunction that may be better than body mass index at stratifying risk and as targets for CVD prevention in the young. Advanced imaging, blood tests and a meal-challenge will be used to comprehensively characterise how early metabolic dysfunction (liver and muscle fat, insulin resistance) affects cardiovascular health (arterial stiffness, myocardial energetics, gut vasoreactivity, diastolic function, blood pressure trajectory, left ventricular hypertrophy) in 210 adolescents (110 obese, 50 sedentary normal-weight, 50 high-activity). Reversibility of this phenotype will be tested in the obese by randomised controlled trial, comparing 8-week supervised exercise to a low-activity sham intervention. This study will provide the platform for developing practical, effective CVD prevention in children that is not simply focused on weight-loss.

Study Overview

Detailed Description

Objectives and Outcome measures

This proposal aims to (1) improve identification of early cardiometabolic dysfunction in children and (2) investigate the reversibility of this dysfunction through exercise. The study will provide the platform for developing practical, effective primordial CVD prevention strategies and the identification of novel early therapeutic targets.

Study Design

This study combines elements of both observational and interventional study designs. A prospective, cross-sectional study of adolescents with 1-year follow-up is combined with a randomised placebo (sham-exercise)-controlled trial (RCT) of eight-weeks of supervised, individualised exercise in an obese sub-population. The RCT is of an established, standardised exercise programme that is low-risk. Group allocation will be known only to the exercise physiologist and staff carrying out the exercise intervention.

Fitness tests will be carried out in schools and in our exercise laboratory, which will provide opportunities to support questionnaire completion, fit accelerometers, fit and return ambulatory blood pressure monitors and address participant questions or concerns. In addition, participants will visit The Oxford Centre for Clinical Magnetic Resonance Research (OCMR) for the initial assessment and for the follow-up assessment for those participants in the obese group.

Participants

210 participants will be recruited, 110 of these will be obese, 50 will be normal weight and their activity will be matched to the obese group and therefore, relatively sedentary. 50 normal weight controls will be selected on the basis of high levels of physical activity. The 110 obese participants will be randomised (1:1) to exercise intervention or a low-intensity sham exercise placebo intervention. These numbers are justified by a priori power calculations and take into account potential withdrawals at an attrition rate of 10% that is compatible with recent studies in the same or similar populations (e.g. Fit to Study). Compliance with the interventions will be increased by carrying out the interventions through an online remote methodology which can also be implemented in a school setting, predominantly during mandatory physical education (PE) lessons. Trained, experienced staff will supervise the exercise sessions, ensuring participant engagement with the activities by measuring heart rate and physical activity levels.

Recruitment

Pre-screening will be done through schools who will write to families informing them that their children will be taking part in an enhanced P.E. lesson at school that includes a fitness and health screening session. As part of this, the children will be asked to wear an activity watch (accelerometer) for a week. The session will explore many aspects of their agility and fitness and assess their muscle strength, power, motor skills, speed, endurance and flexibility, adjusted for their physical size (height and weight). The lesson will be educational, giving personalised feedback to the children on their strengths and how to improve on areas where they are less strong. The school will retain a file linking the children's names to random identifiers but the researchers will not have access to, or retain, any identifiable information. Parents will be sent a letter giving them the opportunity to withdraw their children from this health screening session and explaining that researchers may ask the school to contact them again on their behalf if their children are eligible for study participation on the basis of their fitness assessment. Children who are withdrawn by their parents will participate in their usual P.E. lesson.

Recruitment will be done by letters to parents, delivered via the schools. Recruitment from an established population already in contact with the investigators research group should increase participation rates. It is difficult to precisely estimate the proportion of participants who fulfil the inclusion/exclusion criteria but it is assumed an obesity rate (BMI z-score (WHO) > 2) of approximately 20%.

In addition to the school screening recruitment, participants may also volunteer to take part in the study through our online advertisement and social media campaign. Children who express an interest will be invited to contact the study team so that an initial health assessment can be completed and an information pack can be provided. This pack will contain participant information sheets and consent forms, and will collect information needed for BMI z-score calculation. Then potentially eligible participants will be invited to complete physical activity questionnaires to determine eligibility and group allocation. This is to avoid any unnecessary testing on ineligible participants at university sites and provides a suitable remote method to differentiate between active and inactive participants.

Screening

Pre-stratification of the potential population for recruitment will be carried out, based on BMI and activity levels. Obese and normal weight groups will be approached for recruitment sequentially, according to their rank position within their respective BMI-based criteria in order to maximise the difference between groups (e.g. the most obese will be approached first for the obese group). The normal weight group will be further stratified according to activity levels such that half of this group matches the obesity group for activity whilst the other half are highly-active individuals. Again, individuals within this subgroup will be approached according to their rank position in the distribution of activity such that the most active are preferred in order to maximise the difference between groups.

Informed Consent

Participant's parents/guardians will be asked to sign and date the latest approved version of the Informed Consent before any study-specific procedures are performed. The latest approved Participant Information sheet will be provided to them and verbal explanations will also be provided ensuring that all of the following information has been presented and understood: the exact nature of the study; what it will involve for the participant; the implications and constraints of the protocol; and all known risks or benefits involved in taking part.

Participants will be told that they are free to withdraw from the study at any time and for any reason without being required to give a reason for their withdrawal. The participant will be allowed as much time as they wish to consider the information, and the opportunity to question the Investigator, their General Practitioner (GP) or other independent parties to decide whether they will participate in the study. Once these conditions are satisfied, written Informed Consent will be obtained by means of participant dated signature and dated signature of the person who presented and obtained the Informed Consent. The person taking consent will be a qualified member of the study team with a complete understanding of the study and with the authorisation of the Principal Investigator. A copy of the signed Informed Consent will be given to the participant and the original signed form will be retained at the study site.

Randomisation

Random allocation of members of the obese group to a sham fitness intervention or to a standardised exercise intervention will be carried out using an online randomisation process. The analysis will be carried out on an "intention-to-treat" basis when participants do not complete all elements of the data collection process and single-blinding will be maintained such that members of the team carrying out procedures at OCMR e.g. MRI and those involved in the data analysis are blinded to the allocation of intervention and sham groups. All data acquired at OCMR will be identified by a unique study number only. Inadvertent un-blinding will result in the exclusion of that individual's data from the analysis.

Incidental findings

Cardiovascular findings will be dealt with by the PI or another MRI-trained Consultant Paediatric Cardiologist. Findings in other imaging will be reviewed by the study Paediatric Radiologist. OCMR standard operation procedures (SOPs) for dealing with cardiac and non-cardiac incidental findings, respectively will be followed. Participants will not be informed of incidental findings on the day and will only be contacted after they have been formally reviewed and if a concern remains that further investigation is required.

Discontinuation or withdrawal of participants from the study

Each participant will have the right to withdraw from the study at any time. In addition, participation in the study may be discontinued at any time if the Investigator considers it necessary for any reason, including but not limited to: Pregnancy, ineligibility (either arising during the study or retrospectively, having been overlooked at screening), a significant protocol deviation, significant non-compliance with the exercise regimen or other study requirements, withdrawal of consent, and loss to follow-up. Data gathered to that point will be included in the analysis under an intention-to-treat principle. Where possible, further recruitment will be carried out to compensate for data loss resulting from early discontinuation of participation. The reason for all withdrawals will be recorded in the Case Report Form.

Confounding Factors

The exercise intervention RCT will be carried out over 8 weeks. The MRI scan operator will be blinded to RCT group allocations and all analyses will be carried out on anonymised data. Confounding factors in the observational part of the study will be addressed by matching of groups for age, sex, height, pubertal status and by matching the normal-weight sedentary group on activity level with the obese group. Questionnaires on cardiometabolic risk factors such as diet and sedentary behaviour will be used to quantify potential confounders. At least 24 hours prior to study visits, participants will be asked to avoid strenuous exercise, not smoke or drink alcohol, and eat a standardised evening meal before fasting in the morning.

Analysis

Analyses in the RCT will be carried out on an "intention-to-treat" basis. Secondary exploratory analysis will be to explore mechanisms

Study Type

Interventional

Enrollment (Anticipated)

210

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years to 18 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants willing and able to register their informed assent and whose parent(s)/guardian(s), give informed consent for participation of their child in the study
  • Age and sex-appropriate BMI scores using the World Health Organisation standards for obesity and normal weight
  • Objectively measured physical activity

Exclusion Criteria:

  • Contraindications for exercise intervention as determined by the Physical Activity Readiness Questionnaire
  • Safety issues due to behavioural/intellectual limitations
  • Medical Conditions such as neurological disorders or uncontrolled epilepsy
  • Allergies to dairy
  • Type 1 diabetes
  • Pregnancy
  • Contraindications for Magnetic Resonance scans

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Group
The intervention group will take part in three 1-hour targeted moderate-to-vigorous physical activity (MVPA) gym-based group exercise sessions per week for eight weeks with individualised prescriptions.
Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
Other Names:
  • Exercise Intervention Group
Sham Comparator: Sham-Exercise Group
The shame-exercise group will complete three sham exercise group sessions per week for eight weeks (including stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group).
Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiometabolic phenotype score
Time Frame: Changes from baseline - 8 weeks

An additive cardiometabolic phenotype score will be defined as the sum of the z-scores of known elements of cardiometabolic risk with each element scored such that a positive value indicates greater risk.

The following elements will be scored positively in the risk model: low cardiac phosphocreatine and adenosine triphosphate (PCr/ATP) ratio z-score by phosphate Magnetic Resonance Spectroscopy (MRS), high aortic pulse wave velocity z-score (arterial stiffness) by Magnetic Resonance (MR), high Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) z-score (insulin resistance), high visceral fat mass z-score by T2*-IDEAL MR, high left ventricular mass z-score by MR, low peak left ventricular diastolic filling rate z-score by MR, and high 24 hour ambulatory blood pressure z-score.

Changes from baseline - 8 weeks
Superior mesenteric artery blood flow after a meal challenge
Time Frame: Changes from baseline - 8 weeks
Assessing the change of blood flow (l/min) in the superior mesenteric artery in response to a meal challenge, measured by phase-contrast MR.
Changes from baseline - 8 weeks
Muscle acetylcarnitine
Time Frame: Changes from baseline - 8 weeks
Increased acetylcarnitine is a marker of skeletal muscle metabolism, measured by MRS.
Changes from baseline - 8 weeks
Triglyceride
Time Frame: Changes from baseline - 8 weeks
Blood plasma (mmol/l) post prandial triglyceride response.
Changes from baseline - 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Echocardiography - Diastolic Function
Time Frame: Changes from baseline - 8 weeks
Early mitral inflow velocity and mitral annular early diastolic velocity ratio (E/E' ratio) will be derived from mitral valve inflow Doppler and Tissue Doppler Imaging of the left ventricular myocardium.
Changes from baseline - 8 weeks
High Density Lipoprotein (HDL)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest, measuring cholesterol (mmol/L).
Changes from baseline - 8 weeks
Low Density Lipoprotein (LDL)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest, measuring cholesterol (mmol/L).
Changes from baseline - 8 weeks
Alanine aminotransferase (ALT)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Changes from baseline - 8 weeks
Aspartate Aminotransferase (AST)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Changes from baseline - 8 weeks
Alkaline Phosphatase (ALP)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Changes from baseline - 8 weeks
Total Bilirubin (T.Bil)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Changes from baseline - 8 weeks
Haemoglobin A1c (HbA1c)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest (mmol/L).
Changes from baseline - 8 weeks
Glucose
Time Frame: Changes from baseline - 8 weeks
Serial measures after meal (mmol/L).
Changes from baseline - 8 weeks
Insulin
Time Frame: Changes from baseline - 8 weeks
Serial measures after meal (mmol/L).
Changes from baseline - 8 weeks
Full Blood Count (FBC)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest.
Changes from baseline - 8 weeks
High Sensitivity C-reactive protein (CRP)
Time Frame: Changes from baseline - 8 weeks
Blood samples taken at rest (mmol/L).
Changes from baseline - 8 weeks
Food Preference Questionnaire
Time Frame: Changes from baseline - 4 weeks and 8 weeks
United Kingdom (UK) Biobank Food preference Questionnaire.
Changes from baseline - 4 weeks and 8 weeks
Health Behaviour Questionnaire
Time Frame: Changes from baseline - 4 weeks and 8 weeks
The Health Behaviour in School-Aged Children (HSBC).
Changes from baseline - 4 weeks and 8 weeks
Weight Related Eating Questionnaire
Time Frame: Changes from baseline - 4 weeks and 8 weeks
Weight-Related Eating Questionnaire (WREQ).
Changes from baseline - 4 weeks and 8 weeks
Self-Regulation of Eating Behaviour Questionnaire
Time Frame: Changes from baseline - 4 weeks and 8 weeks
Self-Regulation of Eating Behaviour Questionnaire (SREBQ).
Changes from baseline - 4 weeks and 8 weeks
Physical Activity Levels
Time Frame: Changes from baseline - 8 weeks
Wrist-worn triaxial accelerometers will sample physical activity levels over seven days.
Changes from baseline - 8 weeks
Skeletal muscle lipid
Time Frame: Changes from baseline - 8 weeks
skeletal muscle lipid measured MRS.
Changes from baseline - 8 weeks
Cardiac PCr/ATP ratio
Time Frame: Changes from baseline - 8 weeks
Cardiac PCr/ATP is a measure of myocardial energetics, measure by MRS.
Changes from baseline - 8 weeks
Cardiac lipids
Time Frame: Changes from baseline - 8 weeks
Cardiac lipids is a measure of myocardial lipid spill over, measure by MRS.
Changes from baseline - 8 weeks
Aortic pulse wave velocity
Time Frame: Changes from baseline - 8 weeks
An index of arterial stiffness, measured by MR.
Changes from baseline - 8 weeks
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Time Frame: Changes from baseline - 8 weeks
Measures insulin resistance.
Changes from baseline - 8 weeks
Visceral fat mass
Time Frame: Changes from baseline - 8 weeks
Associated with adverse cardiometabolic changes in adolescents, measured by T2*-IDEAL MR.
Changes from baseline - 8 weeks
Left ventricular mass
Time Frame: Changes from baseline - 8 weeks
A measure of early cardiometabolic dysfunction, measured MR.
Changes from baseline - 8 weeks
Peak left ventricular diastolic filling rate
Time Frame: Changes from baseline - 8 weeks
Indicator of early cardiovascular damage, measure by MR.
Changes from baseline - 8 weeks
Blood pressure
Time Frame: Changes from baseline - 8 weeks
24 hour ambulatory systolic and diastolic blood pressure, measured by SunTech Oscar 2 monitor.
Changes from baseline - 8 weeks
Skeletal muscle glycogen
Time Frame: Changes from baseline - 8 weeks
Increased glycogen is a marker of skeletal muscle metabolism, measured my MRS.
Changes from baseline - 8 weeks
Participant experience
Time Frame: At 8 weeks post baseline and 1 year follow
Optional exit interview of study experience.
At 8 weeks post baseline and 1 year follow

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Alexander Jones, BM, BSc, FRCP, PhD, University of Oxford
  • Study Director: Helen Dawes, PhD, Oxford Brookes University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2019

Primary Completion (Anticipated)

July 1, 2023

Study Completion (Anticipated)

July 1, 2024

Study Registration Dates

First Submitted

September 4, 2019

First Submitted That Met QC Criteria

October 7, 2019

First Posted (Actual)

October 8, 2019

Study Record Updates

Last Update Posted (Actual)

August 12, 2021

Last Update Submitted That Met QC Criteria

August 4, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • R54302/RE001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Overweight/Obesity, Adolescent

Clinical Trials on Intervention Group

3
Subscribe